Tasigna cleared for first-line CML use in Japan
This article was originally published in Scrip
Japan's ministry of health, labour and welfare has confirmed the formal approval of Novartis' Tasigna (nilotinib) for first-line use in chronic myeloid leukaemia (CML), making it only the third such approval for the product worldwide.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.